Examination about the usefulness and life prognosis factor of the beta blocker in sepsis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10965
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Asahikawa Medical College
• Principal Investigator: Motoi Okada 旭川医科大学, 医学部, 准教授 (80431427)
• Co-Investigator(Kenkyū-buntansha): 藤田 智 旭川医科大学, 医学部, 教授 (10173428) ; 西浦 猛 旭川医科大学, 医学部, 客員助教 (90567041) ; 柏木 友太 旭川医科大学, 医学部, 助教 (70648336)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 心不全 / β遮断薬 / 敗血症 / テロメア

Outline of Final Research Achievements

we confirmed the effectiveness of the carvedilol for anti-apoptosis and maintain of the telomeric length with the oxidized cultured cardiomyoblast cell. By the experiment using the mouse CLP model, a suppressant effect and a life prognosis improvement effect were shown a cardiac dysfunction in the carvedilol group. We recognized an expression drop of p53 with the myocardium, expression increase of pgc-1a, tert in the carvedilol group, and mitochondria function improved it more. Even telomeric Q-FISH analysis in a white blood cell accepted extension of the telomere length.
In treatment of the heart failure sepsis-related than the above, carvedilol can expect the restraint of the myocardium mitochondria dysfunction, cardioprotection action heart, a life prognosis improvement effect through the improvement of the energy metabolism.

Free Research Field

心不全